Meteora Capital’s Apexigen, Inc. Common Stock APGN Stock Holding History

Meteora Capital’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-413,243	Closed	-$4.2M	–	468
2022 Q2	$4.2M	Buy	413,243 +84,671	+26%	+$857K	0.8%	33
2022 Q1	$3.31M	Buy	+328,572	New	+$3.3M	1.2%	19

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Meteora Capital's APGN Position: Q3 2022 in Review

Meteora Capital sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 413,243 shares — an estimated $4.2M sold.

Meteora Capital first reported a position in APGN in Q1 2022 and held it in 2 quarters. The position peaked at $4.2M in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

Meteora Capital reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Meteora Capital sold 413,243 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $4.2M.
Meteora Capital first reported a position in Apexigen, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Meteora Capital's Apexigen, Inc. Common Stock position peaked at $4.2M in Q2 2022.
18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Meteora Capital's 13F filing for Q3 2022, filed 14 Nov 2022.